Publications & Presentations

Read our latest ongoing research as we work to advance the standards of care in our therapeutic areas of focus.

Publications

Serdexmethylphenidate/Dexmethylphenidate Capsules for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): A Plain Language Summary

Kollins SH, et al. Future Neurology. 2023; 0026. doi: 10.2217/fnl-2023-0026

View Publication

Serdexmethylphenidate/Dexmethylphenidate for Children with Attention-Deficit/Hyperactivity Disorder: Dose Optimization from a Laboratory Classroom Study

Cutler AJ, et al. Front Psychiatry. 2024; 15, 1310483. doi: 10.3389/fpsyt.2024.1310483

View Publication

A Study of Once-a-Week Donepezil Transdermal System's Bioequivalence to Oral Donepezil in Healthy Volunteers: A Plain Language Summary

Braeckman R, et al. Neurodegen Dis Manage. 2023. doi: 10.2217/nmt-2023-0012

View Publication

Serdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children with Attention-Deficit/Hyperactivity Disorder

Mattingly GW, et al. Front Psychiatry. 2023. 14:1193455. doi: 10.3389/fpsyt.2023.1193455

View Publication

Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate

Childress AC, et al. J Child Adolesc Psychopharmacol. May 2023.134-142. doi: 10.1089/cap.2023.0012

View Publication

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Tariot PN, et al. J Alzheimers Dis. 2022;90(1):161-172. doi: 10.3233/JAD-220530

View Publication

Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study

Childress AC, et al. J Child Adolesc Psychopharmacol. 2023. doi: 10.1089/cap.2022.0076

View Publication

Dose-Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate (SDX)/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder

Braeckman R, et al. J Child Adolesc Psychopharmacol. 2022. doi: 10.1089/cap.2022.0015

View Publication

Oral, Intranasal, and Intravenous Abuse Potential of Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate

Shram MJ, et al. Curr Med Res Opin. 2022;38(7);1237-1250. doi: 10.1080/03007995.2022.2076474

View Publication

A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder

Kollins SH, et al. J Child Adolesc Psychopharmacol. 2021;31(9):597-609

View Publication

Presentations

A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System

Sabbagh M, et al. Presentation. CTAD 2022

View Presentation

A Retrospective Real-World Analysis Demonstrating the Value of AZSTARYS for Patients With Attention-Deficit Hyperactivity

Faraone S, et al. Presentation. Psych Congress 2022

View Presentation

Bioequivalence and Safety Comparison of Once-Weekly Donepezil Transdermal System With Oral Donepezil: Results of a Phase 1 Pharmacokinetic Study in Healthy Volunteers

Tariot P, et al. Presentation. AAIC 2022

View Presentation

Dose Proportionality and Effects of Food on the Pharmacokinetics of Single-Entity Serdexmethylphenidate

Braeckman R, et al. Presentation. APSARD 2022

View Presentation

Evaluation of Skin Adhesion and Local Skin Tolerability of Once-Weekly Donepezil Transdermal System: Results of a Phase 1 Trial in Healthy Volunteers

Tariot P, et al. Presentation. Psych Congress 2022

View Presentation

Mass Balance and Metabolic Pathway Following Oral Administration of [14C]-Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate

Braeckman R, et al. Presentation. APSARD 2022

View Presentation

Serdexmethylphenidate/Dexmethylphenidate for Children With Attention-Deficit Hyperactivity Disorder: Reduction in Disorder Severity From a Laboratory Classroom Study

Childress A, et al. Presentation. Psych Congress 2022

View Presentation

Serdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children With Attention-Deficit Hyperactivity Disorder

Mattingly G, et al. Presentation. Psych Congress 2022

View Presentation

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

Oh C, et al. Presentation. CHADD 2021

View Presentation

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

Oh C, et al. Presentation. American Psychiatric Nurses Association 2021

View Presentation

Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight

Braeckman R, et al. Presentation. AACAP 2021

View Presentation

Steady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate

Braeckman R, et al. Presentation. Psych Congress 2021

View Presentation
Back to top